Catalyst

Slingshot members are tracking this event:

Valeant's (VRX) Bausch + Lomb Resubmits New Drug Application (NDA) for Latanoprostene Bunod Ophthalmic Solution for Lowering Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension

Source Link:
http://www.prnewswire.com/news-releases/bausch--lomb-and-nicox-resubmit-us-new-drug-application-for-novel-glaucoma-candidate-latanoprostene-bunod-300413747.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
VRX
100%
Bausch + Lomb
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 27, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords New Drug Application, Resubmission, Fda, Latanoprostene Bunod, Ophthalmic Solution, Lowering Intraocular Pressure, Open Angle Glaucoma, Ocular Hypertension
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.